Evidence map›Paper›PMID 23910471›Full record

ReviewOtolaryngologic clinics of North America2013

Oral premalignancy: the roles of early detection and chemoprevention.

Jean-Philippe Foy, Chloé Bertolus, William N William, Pierre Saintigny

Open access · greenAbstract readReview
In one paragraph

Review in Otolaryngologic clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 42 citations in OpenAlex.

  1. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.Journal of the National Cancer Institute · 2018
    Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Noninvasive assessment of oral lesions using elastic light single-scattering spectroscopy: a pilot study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2020
    Article
  11. Article
  12. Cancer of the oral cavity.Surgical oncology clinics of North America · 2015
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Jean-Philippe FoyDepartment of Maxillofacial Surgery, Pitié-Salpêtrière Hospital, 47-83 boulevard de l' Hôpital, Paris 75013, France.
Chloé Bertolus
William N William
Pierre Saintigny
Sorbonne Université · FRThe University of Texas MD Anderson Cancer Center · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1M
NCI NIH HHS P30 CA023100NCI NIH HHS P50 CA097007
6 · The paper itself

Abstract

Premalignancy and chemoprevention studies in head and neck cancer typically focus on the oral cavity. Avoiding or cessation of alcohol and smoking, early detection of potentially malignant disorders or cancer, and early detection of recurrent and/or second primary tumor form the basis of prevention of oral cancer. Analysis of tissue prospectively collected in evaluation of retinoids for chemoprevention trials allowed identification of molecular biomarkers of risk to develop oral cancer, loss of heterozygosity being the most validated one. Improving risk assessment and identification of new targets for chemoprevention represent the main challenges in this field.

Indexed as

Carcinoma, Squamous CellChemopreventionEarly DiagnosisHumansLeukoplakia, OralMouth NeoplasmsRetinoidsRetinoidsBiomarkers of riskChemopreventionHead and neck cancerHead and neck squamous cell carcinomaLoss of heterozygocityOral squamous cell carcinomaPotentially malignant disorder

Identifiers

PMID23910471
PMCPMC3734384
OpenAlexW11619671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.